Jay Herath/loyno.edu
Mar 24, 2026, 02:50
Jay Herath: Fitusiran Advancing Hemophilia Care Beyond Factor Replacement
Jay Herath, Professor of the Practice at Loyola University, shared a post on LinkedIn:
“Qfitlia (fitusiran), approved in 2025, is a first-in-class siRNA therapy that treats hemophilia A and B by targeting antithrombin-III mRNA in the liver.
Instead of replacing missing clotting factors (Factor VIII or IX), it reduces antithrombin levels, restoring the body’s ability to generate thrombin and form stable blood clots.”
Stay updated with Hemostasis Today.
-
Mar 24, 2026, 02:53Ney Carter Borges: Circadian Disruption and Melatonin Deficiency as Cardiovascular Risk Factors
-
Mar 24, 2026, 02:52Hamid Noori: Blood Transfusion Types at a Glance
-
Mar 24, 2026, 02:43Kathaleen Schnur: Strong Representation from the Hemophilia Center of Western Pennsylvania at THSN 2026
-
Mar 24, 2026, 02:36Rana Jaber: Uncovering Cardiovascular Harm in Waterpipe Smoking
-
Mar 23, 2026, 17:57Prashant Mukkannavar: Making Pain Assessment Accessible and Culturally Relevant for Stroke Survivors
-
Mar 23, 2026, 17:52Avril Mansfield: Does Walking Asymmetry After Stroke Increase the Risk of Lateral Instability and Falls?
-
Mar 23, 2026, 17:47Katherine Caster: Celebrating The Impact and Continued Leadership of AHA In The Fight Against Heart Disease and Stroke
-
Mar 23, 2026, 17:45Archil Jaliashvili: Oxygen’s Journey – 6 Critical Steps to Power the Cell
-
Mar 23, 2026, 17:42Ney Carter Borges: Contemporary Trends and Outcomes of Percutaneous Coronary Intervention for Stent Thrombosis